Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda:: Multicentre study with multiple and novel assays
Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda:: Multicentre study with multiple and novel assays
复制标题
DOI：
10.1002/jmv.2011
复制
发表时间：
2001-09-01
影响因子：
12.7
通讯作者：
Ensoli, B
中科院分区：
文献类型：
--
作者：
Schatz, O;Monini, P;Ensoli, B
进行了一项多中心研究，以确定新的检测方法，以提高检测间一致性、敏感性、特异性和预测价值，用于人类疱疹病毒 8 型 (HHV-8) 感染的血清学诊断。通过 18 种不同的检测方法，对来自欧洲和乌干达人类免疫缺陷病毒 (HIV) 感染或未感染的患有或不患有卡波西肉瘤 (KS) 的个体和献血者的总共 562 份血清进行了检查。七个欧洲实验室。来自 KS 患者的血清和所有非 KS 血清在检测中至少 70%、80% 或 90% 呈阳性被认为是“真阳性”。然后通过单变量逻辑回归分析评估测定的有效性。两种用于检测针对 HHV-8 裂解 (Rlyt) 或潜伏 (LLANA) 抗原的抗体的免疫荧光测定 (IFA) 和两种用于检测针对 HHV-8 结构蛋白的抗体的酶联免疫吸附测定 (ELISA) (M2、EK8.1) 被发现具有高度一致性、特异性和敏感性，比值比表明具有高预测价值。当一起使用时，两种 IFA (Rlyt-LLANA) 显示出最佳的敏感性 (89.1%) 和特异性 (94.9%) 组合。这些测定的性能表明它们可用于对有发生 HHV-8 相关肿瘤风险的个体（例如同种异体移植受者）进行临床管理。 (C) 2001 Wiley-Liss, Inc.
A multicentre study was undertaken to define novel assays with increased inter-assay concordance, sensitivity, specificity and predictive value for serological diagnosis of human herpesvirus type 8 (HHV-8) infection, A total of 562 sera from European and Ugandan human immunodeficiency virus (HIV)-infected or uninfected individuals with or without Kaposi's sarcoma (KS) and blood donors were examined under code by 18 different assays in seven European laboratories. Sera from KS patients and all non-KS sera found positive by at least 70%,80%, or 90% of the assays were considered "true positive." The validity of the assays was then evaluated by univariate logistic regression analysis. Two immunofluorescence assays (IFA) for detection of antibodies against HHV-8 lytic (Rlyt) or latent (LLANA) antigens and two enzyme-linked-immunosorbent assays (ELISA) (M2, EK8.1) for detection of antibodies against HHV-8 structural proteins were found to be highly concordant, specific, and sensitive, with odds ratios that indicated a high predictive value. When used together, the two IFA (Rlyt-LLANA) showed the best combination of sensitivity (89.1%) and specificity (94.9%). The performance of these assays indicate that they may be used for the clinical management of individuals at risk of developing HHV-8 associated tumours such as allograft recipients. (C) 2001 Wiley-Liss, Inc.